Dr Keith Chappell discusses the bivalent recombinant vaccine for COVID-19 following the study by Dayan and colleagues, with focus on vaccine access, variants and boosters, tolerability and side effects, as well as hopes for future trials.Continue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör The Lancet Group. Innehållet i podden är skapat av The Lancet Group och inte av, eller tillsammans med, Poddtoppen.